Yes, I understand. I also respect your opinion.
Post# of 148258
But have followed many otc companies. I never see the CEO being replaced. I've seen it in nasdaq, but otc I don't see it happen on otc. Probably because the BOD is not as independent as you would see on a nasdaq. To uplist they would have to fix that issue. But changing a CEO on an otc stock is rare. Especially this close to fda approval. Seem very risky if NP has a good relationship with all the interested parties. Maybe the new guy and Lalezari or Patterson or Sacha or Dhody or Maddon or the FDA not mesh, then there goes mono, combo, prep, everything... Huge risk if the BOD believes they are close to approval. Why risk it? Now if they believe we are not, that would be different. We don't know what they know. But I suspect if we could ask, they would say, yes it will get done.